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AbstrACt
background Chronic kidney disease (CKD) is defined by 
abnormalities in kidney structure and/or function present 
for more than 3 months. Worldwide, both the incidence 
and prevalence rates of CKD are increasing. The renin-
angiotensin-aldosterone system (RAAS) regulates fluid and 
electrolyte balance through the kidney. RAAS activation is 
associated with hypertension, which is directly implicated 
in causation and progression of CKD. RAAS blockade, 
using drugs targeting individual RAAS mediators and 
receptors, has proven to be renoprotective.
Objectives To assess genomic variants present within 
RAAS genes, ACE, ACE2, AGT, AGTR1, AGTR2 and REN, for 
association with CKD.
Design and data sources A systematic review and 
meta-analysis of observational research was performed to 
evaluate the RAAS gene polymorphisms in CKD using both 
PubMed and Web of Science databases with publication 
date between the inception of each database and 31 
December 2018. Eligible articles included case–control 
studies of a defined kidney disease and included genotype 
counts.
Eligibility criteria Any paper was removed from the 
analysis if it was not written in English or Spanish, was a 
non-human study, was a paediatric study, was not a case–
control study, did not have a renal disease phenotype, did 
not include data for the genes, was a gene expression-
based study or had a pharmaceutical drug focus.
results A total of 3531 studies were identified, 114 of 
which met the inclusion criteria. Genetic variants reported 
in at least three independent publications for populations 
with the same ethnicity were determined and quantitative 
analyses performed. Three variants returned significant 
results in populations with different ethnicities at p<0.05: 
ACE insertion, AGT rs699-T allele and AGTR1 rs5186-A 
allele; each variant was associated with a reduced risk of 
CKD development.
Conclusions Further biological pathway and functional 
analyses of the RAAS gene polymorphisms will help 
define how variation in components of the RAAS pathway 
contributes to CKD.
IntrODuCtIOn
Chronic kidney disease (CKD) is defined as 
a progressive loss of renal function measured 
as a reduction in glomerular filtration rate 
(GFR) to <60 mL/min/1.73 m2, or the pres-
ence of persistent urinary abnormalities 
including albuminuria and/or structural 
alterations which have been present for at 
least 3 months.1 CKD is an increasing public 
health issue given its associated morbidi-
ties, premature mortality and management 
of advanced CKD is a significant burden on 
healthcare budgets worldwide.2 3 There is 
substantial evidence that inherited genetic 
variants,4 the presence of diabetes5 or hyper-
tension6 and an individual’s ethnicity7 8 
directly influence the development of various 
CKD phenotypes.
The renin-angiotensin-aldosterone 
system (RAAS) is a homeostatic endocrine 
system which is of critical importance to the 
regulation of blood pressure and mainte-
nance of fluid and electrolyte balance.9 10 
Renin (REN), secreted from the juxtaglomer-
ular apparatus in response to reduced renal 
perfusion pressure, catalyses the conversion 
of angiotensinogen (AGT) to angiotensin 
I.11 Subsequently, angiotensin I converting 
strengths and limitations of this study
 ► Individuals with microalbuminuria were exclud-
ed from both the case and control definitions to 
improve the discrimination between individuals 
with and without renal disease as microalbumin-
uria may regress, remain stable or progress to 
macroalbuminuria.
 ► Due to previously reported heterogeneity between 
different ethnic groups, we included this as a risk 
factor and performed each analysis per ethnicity.
 ► Some studies in our search could not be included in 
quantitative analysis as they lacked information re-
lating to genotype counts and had an unclear mea-
sure and definition of albuminuria for both cases and 
controls.
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enzyme (ACE) cleaves angiotensin I to generate angio-
tensin II, which regulates heart and kidney function by 
binding to and activating angiotensin II receptors (type 
I and type II).11 12 The angiotensin II type I receptors 
are responsible for multiple biological actions of RAAS 
including vasoconstriction and sodium reabsorption.11–14
Increased RAAS activation is linked to progression of 
CKD of different aetiologies, especially diabetic nephrop-
athy (DN),11 15–18 and is mediated by hypertensive injury17 
and accelerated renal fibrosis.19 The physiological rele-
vance of this pathway in the progression of CKD has 
focused attention on RAAS components including ACE, 
ACE2, AGT, angiotensin II receptor type 1 (AGTR1), 
angiotensin II receptor type 2 (AGTR2) and renin (REN), 
as candidate genes for various CKD-related phenotypes. 
Multiple studies have implicated RAAS gene variants in 
the progression of CKD.20–26
This manuscript describes a systematic review and 
meta-analysis to examine published data reporting 
genetic variants present within six of the RAAS candidate 
genes: ACE, ACE2, AGT, AGTR1, AGTR2 and REN, for a 
range of CKD phenotypes and ethnicities, to help define 
their putative roles as risk factors for CKD.
MEthODs
search strategy
A systematic search was undertaken following recognised 
methods, the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) guidelines,27 by two investiga-
tors. PubMed and Web of Science online databases were 
searched for studies published between the inception of 
each database and 31 December 2018. All search terms 
are detailed in online supplementary table S1.
The general strategy of the searches was to follow the 
structure: (all alternative versions of each gene name, 
separated by the Boolean operator OR) AND (kidney OR 
nephrology OR nephropathy OR renal) AND (SNP OR 
polymorphism OR variant OR allele OR genotype). For 
each search term, where an appropriate Medical Subject 
Headings (MeSH) term was available, the query included 
the quoted search term OR the MeSH term. Additional 
filters including English OR Spanish languages, human 
studies, case–control studies, not clinical trials, not review 
articles, not a case report and not a meta-analysis were 
applied.
Reference lists from included publications were also 
manually searched. Two authors (LJS and MCG) inde-
pendently conducted the literature search, screened the 
articles and extracted the data. In the case of any disagree-
ment, a third author (RCC) considered the articles. A 
range of CKD phenotypes were included in this analysis, 
the case and control definitions are included in table 1.
Inclusion/exclusion criteria
Inclusion criteria were judged against a standardised 
list of agreed criteria (LJS, MCG and AJM), where the 
English or Spanish language publication described an 
adult, human case–control study of a defined kidney 
disease. In the rare instances when suspected duplicate 
data were identified within two or more included articles, 
only the article either published first, or that with the 
larger number of participants was included.
Articles were excluded if they included paediatric 
subjects, were a pharmacological-based study reporting 
clinical trials of medications, did not contain genotypic 
data for the correct gene or were non-human studies.
Table 1 Phenotypic comparisons included in this analysis
Case group Control group
Autosomal dominant polycystic kidney 
disease
Healthy controls
Atherosclerotic renal artery stenosis Healthy controls
Balkan endemic nephropathy Healthy controls
Chronic glomerulonephritis Healthy controls
Chronic kidney disease Healthy controls
Diabetic nephropathy* Diabetes mellitus
Diabetic nephropathy* Healthy controls
End-stage renal disease Healthy controls
End-stage renal disease Type 1 diabetes mellitus
Focal segmental glomerulosclerosis Healthy controls
Glomerulonephritis Healthy controls
Hypertension-related renal disease Healthy controls with 
hypertension
Hypertension-related renal disease Healthy controls
IgA nephropathy Healthy controls
Interstitial nephritis Healthy controls
Lupus nephritis Systemic lupus 
erythematosus
Lupus nephritis Healthy controls
Minimal change nephrotic syndrome Healthy controls
Non-Balkan endemic nephropathy Healthy controls
Nephroangiosclerosis Healthy controls
Polycystic kidney disease Healthy controls
Primary membranous glomerulonephritis Healthy controls
Primary membranous glomerulonephritis Organ donors
Renal transplant recipients Healthy controls
Renal transplant recipients Kidney donors
Type 1 diabetic nephropathy* Type 1 diabetes mellitus
Type 1 diabetic nephropathy linked to 
end-stage renal disease
Healthy controls
Type 1 diabetic nephropathy linked to 
end-stage renal disease
Type 1 diabetes mellitus
Type 2 diabetic nephropathy* Type 2 diabetes mellitus
Type 2 diabetic nephropathy linked to 
end-stage renal disease
Healthy controls
Type 2 diabetic nephropathy linked to 
end-stage renal disease
Type 2 diabetes mellitus
*In the studies including diabetic nephropathy as cases, only 
individuals with reported macroalbuminuria or proteinuria were 
included. Individuals with microalbuminuria were excluded.
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Data extraction
Where available, the size of each study, case group disease 
definition and number of individuals, control group 
definition and number of individuals, ethnicity, genetic 
variant, genotype in the format of allele 1–heterozygote–
allele 2 and allele counts were recorded and calculated 
in spreadsheets by two authors (LJS and MCG). Articles 
were reassessed where any disagreement occurred and a 
third reviewer was employed. Ethnicities were recorded 
from the articles and recoded following the International 
Genome Sample Resources’ online guidance.28 Where 
any population did not align to a listed population code, 
a new one was created for the purposes of this study. All 
ethnicity codes are available in online supplementary 
table S2. The data collected were divided into disease 
phenotype groups to ensure a high level of homogeneity.
statistical analysis
Each genetic variant which had been investigated and 
reported in at least three independent publications for 
the same ethnicity and phenotype was included in quanti-
tative statistical analyses. Review Manager (RevMan V.5.3) 
(The Cochrane Collaboration, The Nordic Cochrane 
Centre, Copenhagen, Denmark) was employed to facili-
tate the analysis of allele frequencies. For each single nucle-
otide polymorphism (SNP), the total number of alleles 
was recorded per case and control group. Hardy-Wein-
berg equilibrium was calculated for all included studies, 
for cases and controls separately. Statistical analyses were 
performed using the random-effects model as heteroge-
neity was expected. For each SNP, this analysis provided 
the p value, OR and 95% CIs. It also facilitated the assess-
ment of the heterogeneity level using the I2 statistic.29 
Forest plots and funnel plots were generated automati-
cally to assess publication bias and the significance value 
was set at p<0.05 (LJS and RCC).
The genotyping quality of the studies was assessed by 
reported genotype completion rate and Hardy-Weinberg 
equilibrium. Phenotypes included in this analysis are 
shown in table 1; individuals with microalbuminuria were 
excluded alongside the studies that focused on disease 
progression. No sensitivity analysis was performed. All 
study methodologies conformed to the MOOSE criteria.27 
No published protocol is available for this review. The 
workflow followed a consistent pattern for each gene. A 
summary of this is included in figure 1.
Patient and public involvement
Neither patients nor the public were directly involved 
in the design of this study, which analysed previously 
published data available in the public domain.
rEsults
The database searches returned 3531 results, 144 of 
which remained following the application of inclu-
sion and exclusion criteria and the removal of any SNP 
which was not reported on at least three occasions. 
Several articles included data for more than one gene, 
signifying that they have emerged multiple times 
throughout the database searches; the total number of 
individual articles was therefore 114. The search strate-
gies are included as online supplementary figure S1A–F. 
All excluded studies are listed in online supplementary 
table S3A–F.
The total number of subjects analysed within these 
studies (n=114) was 18 231 individuals with renal disease 
and 21 887 individuals acting as controls. For SNPs in 
three of the RAAS genes, ACE2, AGTR2 and REN, there 
were less than three independent populations studied. A 
summary table detailing the main results is included as 
table 2.
Angiotensin converting enzyme
A total of 15 quantitative analyses were completed for 
the insertion/deletion (I/D) polymorphism located 
within ACE in eight phenotypes, details of which are 
included in online supplementary table S4. Three quan-
titative analyses returned a significant result. The first 
analysis comprised 11 publications, each studying an 
East Asian population with type 2 diabetes and nephrop-
athy (T2DN) and compared with type 2 diabetes mellitus 
without nephropathy (T2DM). Figure 2A displays these 
results, p=0.009; OR 0.74; 95% CI 0.59 to 0.93, I2=55%, 
showing that the presence of the insertion variant at this 
ACE locus was significantly associated with this pheno-
type. The insertion provides a lower risk of developing 
T2DN in an East Asian population as demonstrated in 
five studies, which contributed to 51.5% of the weight in 
this analysis. Figure 2B shows the associated funnel plot 
for this analysis.
The ACE insertion variant was similarly significantly 
associated with a lower risk of T2DN compared with 
T2DM in a South Asian population, despite the presence 
of a high level of heterogeneity (p=0.01; OR 0.57; 95% CI 
0.37 to 0.87; I2=89%). This was consistent with the direc-
tion of effect in four studies, which contributed to 67.7% 
of the weight in this analysis (figure 2C). The funnel plot 
for this analysis is displayed within figure 2D. 
The comparison of East Asian individuals with 
end-stage renal disease (ESRD) compared to a healthy 
population with no evidence of renal disease also showed 
a significant association with moderate levels of hetero-
geneity (p=0.08; OR 0.8; 95% CI 0.67 to 0.94; I2 68%). 
Four studies, supporting 69.7% of the weight in the anal-
ysis had shown this effect (figure 2e). Figure 2f shows the 
associated funnel plot for this analysis. 
In each analysis (T2DN vs T2DM; end-stage renal 
disease [ESRD] vs normal), the presence of the ACE 
insertion was associated with a lower risk of developing 
the CKD phenotype in the respective populations. The 
non-significant forest plots are included in online supple-
mentary figure S2A–I and the associated funnel plots 
within online supplementary figure S3A–I.
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Angiotensinogen
Seven quantitative analyses were completed for rs699, 
where the T allele was compared with the C allele. 
Details of each of these comparisons are included in 
online supplementary table S5. One significant result 
was identified—the comparison of ESRD with healthy 
controls in a European population. The results were 
(p=0.002; OR 0.84; 95% CI 0.76 to 0.94; I2=0%) and 
are shown in figure 2G. Only the study with population 
size over 2000 patients, supporting 46.2% of the weight 
in the meta-analysis, had achieved significance with the 
original figures. These results indicate that the presence 
of the T allele is associated with a lower risk of devel-
oping ESRD in this population. The funnel plot for this 
analysis is displayed within figure 2H. The forest plots 
containing the non-significant results are included in 
Figure 1 Workflow pattern. RAAS, renin-angiotensin-aldosterone system; SNP, single nucleotide polymorphism. 
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online supplementary figure S4A–F, and the associated 
funnel plots within online supplementary figure S5A–F.
Angiotensin II receptor type 1
Four quantitative analyses were performed for AGTR1 
rs5186, comparing the A allele with the C. Details of these 
comparisons are included within online supplementary 
table S6. One of the four studies returned a significant 
result for association, the comparison of T2DN with 
T2DM in a South Asian population (p=0.001; OR 0.71; 
95% CI 0.58 to 0.87; I2=37%). This result resembled 
the findings of two of the three studies which contrib-
uted 87% of the weight in the meta-analysis, as shown 
in figure 2I. Figure 2J contains the associated funnel 
plot. These results indicate that the presence of the A 
allele is associated with a lower risk of developing T2DN 
in this population. The non-significant results in forest 
plot format are included in online supplementary figure 
S6A–C and in funnel plot format within online supple-
mentary figure S7A–C.
Studies not complying with Hardy-Weinberg equilib-
rium are shown in online supplementary table S7. Allele 
frequencies for healthy control populations included in 
this analysis were assessed. None showed signs of bias in 
any included study, in comparison to all available dbSNP 
reported frequencies as shown in online supplemen-
tary file S1.
DIsCussIOn
Investigations into RAAS genetic variants previously 
reported to have been associated with a range of CKD 
phenotypes were undertaken. A total of 3531 studies were 
identified, 114 of which met the inclusion criteria. Subse-
quently, 26 quantitative analyses were completed for 
three RAAS genes where there were at least three inde-
pendent population studies of the RAAS gene variants. 
Five significant results within three genes were obtained 
at the significance level p<0.05, each revealing an associ-
ation with CKD.
ACE is encoded by DCP1 and is a key component of 
the RAAS. It catalyses the modification of angiotensin I 
to II, which is more biologically active.30 ACE is the most 
frequently studied gene of the RAAS.31 First sequenced 
in 1992,32 this 287 bp Alu repetitive element at intron 
1632 is located on chromosome 17 and is represented by 
four individual SNPs: rs4646994, rs1799752, rs4340 and 
rs13447447. Further understanding of its genetic architec-
ture and disease associations may enable patient groups 
to benefit from targeted therapies with ACE inhibitors.33
Since 1994, the association of ACE and DN has been 
rigorously investigated,33 34 with studies returning 
conflicting results. A meta-analysis undertaken in 2005 
by Ng and colleagues35 reported a statistically signifi-
cant result wherein the ACE insertion was associated 
with protection from development of DN in Asians and 
Caucasians. A second meta-analysis undertaken in 2012 
also identified an association between the ACE I/D T
ab
le
 2
 
S
um
m
ar
y 
of
 t
he
 m
os
t 
si
gn
ifi
ca
nt
 r
es
ul
t 
fo
r 
ea
ch
 in
cl
ud
ed
 g
en
e
G
en
e
A
rt
ic
le
s 
re
tu
rn
ed
 (n
)
A
rt
ic
le
s 
an
al
ys
ed
 (n
)
M
ax
im
um
 
in
d
iv
id
ua
ls
 in
 
an
al
ys
is
 (n
)
M
o
st
 
si
g
ni
fi
ca
nt
 
re
su
lt
P
 v
al
ue
O
R
 (9
5%
 C
I)
I2
 (%
)
A
lle
le
A
ve
ra
g
e 
al
le
le
 
fr
eq
ue
nc
y—
co
nt
ro
ls
A
C
E
38
0
95
33
 2
47
I/
D
 (E
A
S
)
0.
00
8
0.
80
 (0
.6
7 
to
 0
.9
4)
68
In
se
rt
io
n
0.
62
A
C
E
2
15
56
0
N
A
N
A
N
A
N
A
N
A
N
A
A
G
T
69
3
33
13
 2
34
rs
69
9 
(E
U
R
)
0.
00
2
0.
84
 (0
.7
6 
to
 0
.9
4)
0
T
0.
57
A
G
TR
1
20
0
16
69
17
rs
51
86
 (S
A
S
)
0.
00
1
0.
71
 (0
.5
8 
to
 0
.8
7)
37
A
0.
81
A
G
TR
2
29
0
N
A
N
A
N
A
N
A
N
A
N
A
R
E
N
67
3
0
N
A
N
A
N
A
N
A
N
A
N
A
E
A
S
, E
as
t 
A
si
an
; E
U
R
, E
ur
op
ea
n;
 I/
D
, i
ns
er
tio
n/
d
el
et
io
n;
 N
A
, n
ot
 a
p
p
lic
ab
le
; S
A
S
, S
ou
th
 A
si
an
.
 o
n
 2 M
ay 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-026777 on 1 May 2019. Downloaded from 
6 Smyth LJ, et al. BMJ Open 2019;9:e026777. doi:10.1136/bmjopen-2018-026777
Open access 
polymorphism and the development of DN to ESRD, 
in that the presence of the deletion was associated with 
ESRD susceptibility.36 Despite having differences in the 
inclusion criteria to our meta-analysis, in that these inves-
tigations did not include any article published since 
201135 36 and included individuals with microalbuminuria 
as cases,35 we returned similar results to the 2005 previous 
meta-analysis. Including individuals with microalbumin-
uria in the control population may cause challenges with 
phenotype definition as microalbuminuria may regress, 
remain stable or progress to macroalbuminuria37–39 over 
time. Individuals with microalbuminuria were therefore 
Figure 2 Forest and funnel plots for statistically significant results. (A) Forest plot—ACE insertion/deletion (I/D) investigation, 
individuals with type 2 diabetic nephropathy compared with individuals with type 2 diabetes mellitus in an East Asian 
population (ACE insertion compared with deletion). (B) Funnel plot—ACE I/D investigation, individuals with type 2 diabetes and 
nephropathy compared with individuals with type 2 diabetes mellitus (without nephropathy) in an East Asian population (ACE 
insertion compared with deletion). (C) Forest plot—ACE I/D investigation, individuals with type 2 diabetes and nephropathy 
compared with individuals with type 2 diabetes mellitus (without nephropathy) in a South Asian population (ACE insertion 
compared with deletion). (D) Funnel plot—ACE I/D investigation, individuals with type 2 diabetic nephropathy compared with 
individuals with type 2 diabetes mellitus in a South Asian population (ACE insertion compared with deletion). (E) Forest plot—
ACE I/D investigation, individuals with end-stage renal disease compared with healthy controls in an East Asian population (ACE 
insertion compared with deletion). (F) Funnel plot—ACE I/D investigation, individuals with end-stage renal disease compared 
with healthy controls in an East Asian population (ACE insertion compared with deletion). (G) Forest plot—angiotensinogen 
(AGT) rs699 investigation, individuals with end-stage renal disease compared with healthy controls in a European population 
(AGT rs699 T allele compared with C allele). (H) Funnel plot—AGT rs699 investigation, individuals with end-stage renal 
disease compared with healthy controls in a European population (AGT rs699 T allele compared with C allele). (I) Forest 
plot—angiotensin II receptor type 1 (AGTR1) rs5186 investigation, individuals with type 2 diabetic nephropathy compared with 
individuals with type 2 diabetes mellitus in a South Asian population (AGTR1 rs5186 A allele compared with C allele). (J) Funnel 
plot—AGTR1 rs5186 investigation, individuals with type 2 diabetes and nephropathy compared with individuals with type 2 
diabetes mellitus (without nephropathy) in a South Asian population (AGTR1 rs5186 A allele compared with C allele).
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excluded from both case and control definitions to clarify 
the phenotypes in our review.
In our meta-analysis of ACE, which comprised 15 265 
individuals with CKD and 18 474 individuals as controls 
from 98 population groups, we identified three significant 
associations of the ACE I/D polymorphism with CKD. Due 
to previously reported heterogeneity between different 
ethnic groups,35 we included this as a risk factor and 
performed each analysis per ethnicity (see online supple-
mentary table S2). Despite some of the allele frequency 
distributions varying across different ethnicities, the 
direction of the effect was consistent among the different 
ethnicities: where populations had different minor allele 
frequencies (MAFs), they often reported similar ORs in 
the meta-analysis.
First, comparisons between T2DN and T2DM in East 
Asian and South Asian populations returned signif-
icant results highlighting a protective effect of the 
ACE insertion in the development of DN (p=0.009 and 
p=0.01, respectively). This result was mimicked in the 
comparison of individuals with ESRD, which was not 
caused by DN, and healthy control individuals in an East 
Asian population (p=0.008). The ACE I/D polymorphism 
remains a well-characterised genetic locus associated with 
the progression of DN.
AGT encodes the AGT glycoprotein, which is created in 
the liver and facilitates the creation of angiotensin I.11 40 It 
is located on chromosome 1. Several investigations have 
been conducted into the AGT gene variants and their 
association with risk of CKD.40–43 Among these, Zhou and 
colleagues undertook a meta-analysis investigation into 
AGT rs699 and its association with ESRD.40 The results 
of this study are in agreement with ours in relation to 
the European ethnicity. Our meta-analysis encompassing 
5463 individuals with renal disease and 6385 individuals 
without; the T allele provided a protective effect in ESRD 
development (p=0.002) within this European population.
In European and Middle Eastern populations, the allele 
distribution of rs699 was very similar to the comparison 
of T2DN versus T2DM, yet different from the East Asian 
population. This may have had an impact on the results, 
potentially limiting the robustness of association analyses 
across ethnicities.
The AGTR1 gene has been shown to be involved in 
the regulation of blood pressure, fluid and electrolyte 
balance.11 It may also have a role in inflammation and 
vasoconstriction.44 SNP rs5186, an AC nucleotide substi-
tution at position 1166 in the 3′ untranslated region 
of chromosome 3, is reportedly able to be recognised 
by microRNA-155. When the A allele is present at this 
locus, microRNA-155 is able to undergo complementary 
base pairing with AGTR1 messenger RNA to suppress 
translation. However, this is not possible when the alter-
native C allele is present, resulting in increased AGTR1 
protein levels.45 This interplay may affect blood pressure 
regulation and warrants further investigation.45
Previous studies have identified associations between 
rs5186 in AGTR1 and diseases including coronary artery 
disease,46 systemic lupus erythematosus47 and cancer.48 
Several smaller studies had also been undertaken to 
assess links between this gene and renal disease.25 49–54 We 
conducted this study to provide a clearer understanding 
of the effect of this SNP on CKD.
This meta-analysis of AGTR1 variants included 3197 
individuals with renal disease and 3720 controls investi-
gating rs5186. One significant result was identified: that 
the presence of an A allele at this locus provided a lower 
risk of developing T2DN in a South Asian population 
(p=0.001).
One meta-analysis published in 201455 assessed AGTR1 
in individuals with CKD, ESRD, IgA nephropathy or vesi-
coureteral reflux. This meta-analysis identified that rs5186 
was not associated with any of these diseases, which corre-
sponds to the results from our investigation.
The three remaining RAAS genes included in this 
meta-analysis, ACE2, AGTR2 and REN, have not been 
researched as extensively as ACE, AGT and AGTR1 for 
associations with renal disease. Very few articles were 
identified describing genetic association studies for 
these genes at the data extraction stage of the analysis, 
and those that were removed prior to the quantitative 
analysis stage, mainly due to the inclusion of paediatric 
individuals or non-human approaches, as outlined in 
online supplementary figure S1B,E,F. Further research 
into the ACE2, AGTR2 and REN genes and their poly-
morphisms should be undertaken to elucidate their 
role in CKD and ESRD.
Some studies in our search could not be included in 
quantitative analysis as they lacked information relating 
to genotype counts and had an unclear measure and 
definition of albuminuria for both cases and controls, 
which could constitute a limitation. Results from 
genome-wide association studies would have strength-
ened the analysis, but unfortunately they usually only 
report significant SNPs. Absolute frequencies are not 
usually reported at individual SNP level for such large-
scale studies. Publication bias was reported in two of 
our quantitative analyses, but was not found in the 
analyses which provided our significant results. Lack 
of clarity in phenotype definitions, along with unclear 
descriptions of ethnicities, inherently challenge the 
use of meta-analyses of different populations as a valid 
instrument to uncover robust associations. CKD itself 
has a range of causes including glomerular damage and 
declining estimated GFR without albuminuria. Other 
confounding factors such as hypertension and cardio-
vascular disease, and a lack of prospective follow-up of 
included individuals, which would ensure phenotypes 
are robust and stable, may also cause conflicting results.
COnClusIOn
This meta-analysis of the RAAS pathway genes and their 
association with renal disease has provided evidence for 
five significant associations with individually small effect 
sizes that may cumulatively contribute to dysfunction 
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of the RAAS pathway leading to kidney disease. The 
insertion in ACE I/D polymorphism was a protection 
factor for the development of DN in individuals with 
type 2 diabetes mellitus from both East and South Asian 
origin, and for ESRD in an East Asian population. In 
Europeans, the T allele of the AGT rs699 conferred a 
lower risk of ESRD development in healthy population. 
The A allele in AGTR1 rs5186 acted as a protection 
factor for renal disease development in South Asian 
population.
Further study into the specific ethnicities and investi-
gations into a broader range of RAAS-linked genes, or a 
deeper analysis of them including investigations of more 
variants, may pinpoint the molecular basis underlying the 
role of pathway in kidney disease. Network analysis and 
functional studies enlightening the mechanisms involved 
ultimately will be required to complete the picture of 
RAAS variation in renal traits.
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